CHPA applauds FDA for taking a critical step forward today in public health, which will remove many of the barriers and stigmas attached to this life-saving emergency therapy for opioid overdoses
CHPA released the below statement today following the U.S. Food and Drug Administration’s announcement that it will postpone its previously scheduled April 12 Nonprescription Drugs Advisory Committee meeting to reconsider the efficacy of oral phenylephrine.
Good science, and new customer behavior mean the time is right for companies to evaluate their portfolios to position themselves for success. Tailwinds are good, private equity interest is high, and the self-care future is bright.
CHPA tracks FDA progress vs. OMUFA goals and activities referenced in legislation. These goals were negotiated between the Agency and Industry prior to the legislation and cover the 5-year period for OMUFA I (October 1, 2020 – September 30, 2025).
The Consumer Healthcare Products Association (CHPA) released the following statement in advance of FDA Advisory Committee meetings considering OTC access to naloxone
The purpose of this cybersecurity and data privacy regulatory scan is to understand the current and forthcoming regulatory landscape related to cybersecurity and consumer data privacy.
